EUVIMEDEUVIMED entdecken
Crossref

Nitroxide radical conjugated ovalbumin theranostic nanosystem for enhanced dendritic cell-based immunotherapy and T1 magnetic resonance imaging

Yike Hou, Fei Kong, Zhe Tang, Rui Zhang, Dan Li, Jian Ge, Zhangsen Yu, Abdul Wahab, Yunyang Zhang, M Zubair Iqbal, Xiangdong Kong

Journal of Controlled Release · 2024

DOI: 10.1016/j.jconrel.2024.07.050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Yike Hou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Smart Biomedical Materials, School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, PR China; Zhejia…. Hauptthemen laut MEDLINE: Dendritic Cells, Immunotherapy, Magnetic Resonance Imaging, Theranostic Nanomedicine. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma, known for its aggressive metastatic nature, presents a formidable challenge in cancer treatment, where conventional therapies often fall short. This study introduces a pioneering approach utilizing metal-free nanosystem as tumor vaccines, spotlighting their potential in revolutionizing melanoma treatment. This work employed organic nitroxides, specifically 4-carboxy-TEMPO, in combination with chitosan (CS), to create a novel nanocomposite material - the CS-TEMPO-OVA nanovaccines. This composition not only improves biocompatibility and extends blood circulation time of TEMPO but also marks a significant departure from traditional gadolinium-based contrast agents in MRI technology, addressing safety concerns. CS-TEMPO-OVA nanovaccines demonstrate excellent biocompatibility at both the cellular and organoid level. They effectively stimulate bone marrow-derived dendritic cells (BMDCs), which in turn promote the maturation and activation of T cells. This ultimately leads to a strong production of essential cytokines. These nanovaccines serve a dual purpose as both therapeutic and preventive. By inducing an immune response, activating cytotoxic T cells, and promoting macrophage M1 polarization, they effectively inhibit melanoma growth and enhance survival in mouse models. When combined with αPD-1, the CS-TEMPO-OVA nanovaccines significantly bolster the infiltration of cytotoxic T lymphocytes (CTLs) within tumors, sparking a powerful systemic antitumor response that effectively curbs tumor metastasis. The ability of these nanovaccines to control both primary (subcutaneous) and metastatic B16-OVA tumors highlights their remarkable efficacy. Furthermore, the CS-TEMPO-OVA nanovaccine can be administered in vivo via both intravenous and intramuscular routes, both of which effectively enhance the T1 contrast of magnetic resonance imaging in tumor tissue. This study offers invaluable insights into the integrated application of these nanovaccines in both clinical diagnostics and treatment, marking a significant stride in cancer research and patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsImmunotherapyMagnetic Resonance ImagingTheranostic NanomedicineMice, Inbred C57BLOvalbuminChitosanAnimalsCancer VaccinesFemaleCyclic N-OxidesMelanoma, ExperimentalMiceCell Line, TumorNitrogen Oxides

Stichwörter der Autor:innen

Cancer immunotherapyCancer vaccineContrast agentMagnetic resonance imagingNitroxide radicalOvalbumin

Substanzen

OvalbuminChitosanCancer VaccinesCyclic N-OxidesNitrogen OxidesTEMPO

Autor:innen und Institutionen

  • Institute of Smart Biomedical Materials, School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, PR China; Zhejiang-Mauritius Joint Research Center for Biomaterials and Tissue Enginee…
  • College of Life Sciences, China Jiliang University, 258 XueYuan Street, XiaSha Higher Education Zone, Hangzhou 310018, Zhejiang, PR China.
  • Laboratory of Nanomedicine, Medical Science Research Center, School of Medicine, Shaoxing University, Shaoxing City, Zhejiang Province 312000, PR China.

Zitieren

APA

Hou, Y., Kong, F., Tang, Z., Zhang, R., Li, D., Ge, J., Yu, Z., Wahab, A., Zhang, Y., Iqbal, M. Z., & Kong, X. (2024). Nitroxide radical conjugated ovalbumin theranostic nanosystem for enhanced dendritic cell-based immunotherapy and T1 magnetic resonance imaging. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.07.050

Vancouver

Hou Y, Kong F, Tang Z, Zhang R, Li D, Ge J, et al. Nitroxide radical conjugated ovalbumin theranostic nanosystem for enhanced dendritic cell-based immunotherapy and T1 magnetic resonance imaging. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.07.050

BibTeX
@article{Hou2024,
  author = {Hou, Yike and Kong, Fei and Tang, Zhe and Zhang, Rui and Li, Dan and Ge, Jian and Yu, Zhangsen and Wahab, Abdul and Zhang, Yunyang and Iqbal, M Zubair and Kong, Xiangdong},
  title = {Nitroxide radical conjugated ovalbumin theranostic nanosystem for enhanced dendritic cell-based immunotherapy and T1 magnetic resonance imaging},
  journal = {Journal of Controlled Release},
  year = {2024},
  doi = {10.1016/j.jconrel.2024.07.050}
}
Kostenlos starten →